A review of irritable bowel syndrome and an update on therapeutic approaches

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 7, 2008, Pages 1129-1143

  Bassett, John T ^a   Cash, Brooks D ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Alosetron; Gabapentin; Irritable bowel syndrome; Linaclotide; Lubiprostone; Nepadutant; Rifaximin; Saredutant; Tegaserod

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALVIMOPAN; ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; ASIMADOLINE; BULKING AGENT; CLONIDINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DESIPRAMINE; DICYCLOVERINE; GABAPENTIN; GASTROINTESTINAL AGENT; GUANYLATE CYCLASE ACTIVATOR; LIDOCAINE; LINACLOTIDE; LUBIPROSTONE; NEOMYCIN; NEPADUTANT; OPIATE ANTAGONIST; PLACEBO; PREGABALIN; PROBIOTIC AGENT; RENZAPRIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SPASMOLYTIC AGENT; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; CHOLINERGIC RECEPTOR BLOCKING AGENT; LAXATIVE;

ABDOMINAL PAIN; ACUPUNCTURE; BLOOD CELL COUNT; BLOOD CHEMISTRY; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COLON BIOPSY; COLON DILATATION; COMORBIDITY; COST BENEFIT ANALYSIS; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; ENTERITIS; FECES ANALYSIS; GENETIC PREDISPOSITION; HEALTH CARE COST; HEART ARRHYTHMIA; HUMAN; HYDROGEN BREATH TEST; HYPNOSIS; ILEUS; INTESTINAL DYSMOTILITY; INTESTINE ENDOSCOPY; IRRITABLE COLON; LOOSE FECES; LOW DRUG DOSE; NAUSEA; NONHUMAN; OCCULT BLOOD; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SEX DIFFERENCE; SINGLE DRUG DOSE; THYROID FUNCTION TEST; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN; DIETARY FIBER; DRUG DELIVERY SYSTEM;

ANTIDIARRHEALS; DIETARY FIBER; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; LAXATIVES; PARASYMPATHOLYTICS;

EID: 43049168690     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.7.1129     Document Type: Review

References (108)

1. Manning AP, Thompson WG, Heaton KW, et al. Towards a positive diagnosis of the irritable bowel syndrome. BMJ 1978;2:653-4
2. Thompson WG, Dotewall G, Drossman DA, et al. Irritable bowel syndrome: guidelines for the diagnosis. Gastroent Int 1989;2:92-5
3. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999;45(Suppl II):II43-7
4. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91
5. Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-5
6. Podovei M, Kuo B. Irritable bowel syndrome: a practical review. South Med J 2006;99(11):1235-42
7. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140-56
8. Azpiroz F, Dapoigny M, Pace F, et al. Nongastrointestinal disorders in the irritable bowel syndrome. Digestion 2000;62:66-72
9. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990;99:409-15
10. Talley NJ, Gabriel SE, Harmsen WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736-41
11. Sandler RS, Everhart JE, Donowicz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002;122:1500-11
12. Muller-Lissner SA, Pirk O. Irritable bowel syndrome in Germany. A cost of illness study. Eur J Gastroenterol Hepatol 2002;14:1325-9
13. Malcolm A. Philips SF, Kellow JE, et al. Direct clinical evidence for spinal hyperalgesia in patients with irritable bowel syndrome. Am J Gastroenterol 2001;96:2427-31
14. Chan YK, Herkes GK, Badcock C, et al. Alterations in cerebral evoked potentials evoked by rectal distention in irritable bowel syndrome. Am J Gastroenterol 2001;96:2413-7
15. Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842-8
16. Drossman D, Ringel Y, Voight BA, et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 2002;124:754-61
17. Lawal A, Kern M, Sidhu H, et al. Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients. Gastroenterology 2006;130:26-33
18. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83
19. Tornblom H, Lindberg G, Nyberg B, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in the irritable bowel syndrome. Gastroenterology 2002;123:1972-9
20. Spiller RC. Infection, immune function, and functional gut disorders. Clin Gastroenterol Hepatol 2004;2(6):445-55
21. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292(7):852-8
22. Sanders DS, Carter MJ, Hurlstone DP. Association of adult celiac disease with irritable bowel syndrome: a case-control study in patients fulfilling the Rome II criteria referred to secondary care. Lancet 2001;358:1504-8
23. Barbara G, Degiorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004;20(Suppl 2):1-9
24. Spiller RC, Jenkins D, Thomley JP. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47(6):804-11
25. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132(1):26-37
26. Serna H, Porras M, Vergara P. Mast cell stabilizer kerotifen prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental T. spiralis inflammation in the rat. J Pharmacol Exp Ther 2006;319(3):1104-111
27. Barau E, Dupont C. Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome. J Pediatr Gastroenterol Nutr 1990;11(1):72-7
28. Bericik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005;34:235-45
29. Bazocchi G, Ellis J, Villaneuva-Meyer J, et al. Colonic scintigraphy and manometry in constipation, diarrhea, and inflammatory bowel disease. Gastroenterology 1988;94:A29
30. Cann PA, Read NW, Brown C, et al. Irritable bowel syndrome. Relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983;24:405-11
31. Bazocchi G, Ellis J, Villaneuva-Meyer J, et al. Postprandial colonic transit and motor activiry in chronic constipation. Gastroenterology 1990;98:686-93
32. Drossman DA. Lesserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990;113:828-33
33. Walker EA, Gelfand AN, Gelfand MD, et al. Medical and psychiatric symptoms in female gastroenterology clinic patients with histories of sexual victimization. Gen Hosp Psychiatry 1995;17:85-92
34. Lesserman J, Drossman DA, Li Z, et al. Sexual and physical abuse history in gastroenterology practice: how types of abuse impact health status. Psychosom Med 1996;58:4-15
35. Miller AR, North CS, Clouse RE, et al. The association of irritable bowel syndrome and somatization disorder. Ann Clin Psychiatry 2001;13:25-30
36. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidiry of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140-56
37. Drossman DA, Camilled M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31
38. Cash BD, Schoenfeld PS, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002;97:2812-9
39. Hamm LR, Sorrells SC, Harding JP, et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol 1999;94:1279-82
40. Tolliver BA, Herrera JL, Dipalma JA. Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am J Gastroenterol 1994;89:176-8
41. Macintosh DG, Thompson WG, Patel DG, et al. Is rectal biopsy necessary in irritable bowel syndrome? Am J Gastroenterol 1992;87:1407-9
42. Francis CY, Duffy JN, Whorwell PJ, et al. Does routine ultrasound enhance diagnostic accuracy in irritable bowel syndrome? Am J Gastroenterol 1990;91:1348-50
43. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling the ROME II criteria referred to secondary care. Lancet 2001;358:1504-8
44. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6
45. 2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994;343:811-6
46. Lassen AT, Pedersen FM, Bytzer P, et al. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomized trial. Lancet 2000;356(9228):455-60
47. Quartero AO, Meineche-Schmidt V, Muris J, et al. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2005;2:CD003460
48. Lesbros-Pantoftickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1253-69
49. Bijkerk CJ, Muris JW, Knottnerus JA, et al. Systematic review: the role of different types of fiber in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;19:245-51
50. Wheatley D. Irritable colon syndrome treated with an antispasmodic drug. Practitioner 1976;217:276-80
51. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981;3:153-6
52. Ritchie JA, Truelove SC. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. BMJ 1979;1:376-8
53. Schafer E, Ewe K. Behandlung des colon irritable. Fortschr Med 1990;108:488-92
54. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional bowel gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72
55. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-Behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31
56. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-17
57. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99(5):914-20
58. Tack J, Brockaert D, Fischler B, et al. A controlled cross-over study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55(8):1095-103
59. Fukudo S, Namura T, Hongo M. Impact of corticotrophin-releasing hormone on gastrointestinal motility and adrenocorticotrophic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998;42:845-9
60. Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotrophin-releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004;53:958-64
61. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-70
62. 3 receptor antagonist. Aliment Pharmacol Ther 1999; 13:1149-59
63. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomized, placebo-controlled trial. Lancet 2000;355:1035-40
64. Jones RH, Holtmann G, Rodrigo L, et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female non-constipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999;13:1419-27
65. Chey WD, Cash BD. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin Invest Drugs 2005;14(2):1-9
66. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002,16:877-88
67. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-6
68. US Food and Drug Administration Center for Drug Evaluation and Research. Public health advisory tegaserod maleate 30 March 2007. Available from: http://www.fda.gov/cder/drug/advisory/tegaserod.htm [Last accessed 12 November 2007]
69. Camilleri M, Mckinzie S, Fox J, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2004;2:895-904
70. George A, Meyers NL. Palmer RMJ. Efficacy and safety of renzapride in constipation-predominant IBS: a Phase IIB study in the UK primary healthcare setting. Gut 2003;52(SVI):A91
71. Meyers N, Hicking R. The cardiovascular safety profile of renzapride, a novel treatment for irritable bowel syndrome. J Int Med Res 2007;35:848-66
72. Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol Motil 2005;17(2):157-65
73. Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006;20(1):64-70
74. Delaney CP, Weese JL, Hyman NH, et al. Phase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgery. Dis Colon Rectum 2005;48(6):1114-25
75. Meeting of the Gastrointestinal Drugs Advisory Committee (GIDAP) to evaluate entereg (Alvimopam) for the acceleration of recovery time of upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastamosis. January 23, 2008. Available from: http://www.fda.gov/ohrms/dockets/AC/08/briefing/ 2008-4336b1-01-FDA.pdf [Last accessed 10 February 2008]
76. Delgado-Aros S, Chial HJ, Camilleri M, et al. Effects of a κ opioid agonist, asimodoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol 2002;284:G558-66
77. Delvaux M, Beck A, Jacob J, et al. Effect of asimodoline, a κ opioid agonist, on pain induced by colonic distention in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:237-46
78. Lordal M, Navalesi G, Theodornsson E, et al. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001;134:215-23
79. Evangelista S. Talnetant. Curr Opin Invest Drugs 2005;6:717-21
80. Sanger GJ. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br J Pharmacol 2004;141:1303-12
81. 2-adrenergic agonist on gastrointestinal transit, colonic motility and sensation in humans. Am J Physiol 2001;281:G1468-76
82. Camilleri M, Kim DY, McKinzie S, et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003;1:111-21
83. Horvath EJ, Palkovits M, Lenkei A, et al. Autoradiographic localization and quantitative determination of specific binding sites of anxiolytic homophthalzaines (formerly called 2,3 benzodiazepines) in the striato-pallido-nigral systems of rats. Brain Res Mol Brain Res 1994;22:211-8
84. Horvath EJ, Horvath K, Hamori T, et al. Anxiolytic 2,3, benzodiazepines, their specific binding to the basal ganglia. Prog Neurobiol 2000;60:309-42
85. Leventer S, Raudibaugh K, Frissora C, et al. The safety and efficacy of dextofisopam in patients with diarrhea-predominant or alternating irritable bowel syndrome. Gastroenterology 2005;128:A94
86. Johanson JF, Panas R, Holland PC, et al. A dose-ranging, double-blind, placebo-controlled study of lubiprostone in patients with irritable bowel syndrome with constipation. Gastroenterology 2006;130.A25
87. Drossman DA, Chey W, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve week, randomized, placebo-controlled, double-blind trials. Gastroenterology 2007;132:2586-7
88. Johanson JF, Gargano M, Holland PC, et al. Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. Gastroenterology 2003;124(Suppl 1):A48
89. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-9
90. Pimentel M, Charterjee S, Chow EJ, et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006;51:1297-301
91. Pimentel M, Park S, Kane SV. Rifaximin, a nonabsorbable, gut-selective antibiotic, improves the symptoms of irritable bowel syndrome: a randomized, double-blind, placebo-controlled study. Ann Intern Med 2006;145:557-63
92. Harris LA, Crowell MD. Drug evaluation: linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther 2007;9:403-10
93. Anderson V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133(3):761-8
94. Curry MG, Kurtz C, Mahajan-Mildos S, et al. Effects of a single dose administration of MD-1100 on safety, tolerability. exposure, and stool consistency in healthy subjects. Am J Gastroenterol 2005;100(9):S328
95. Verne GN, Sen A, Price DD. Intrarectal lidocaine is an effective treatment for abdominal pain associated with diarrhea-predominant irritable bowel syndrome. J Pain 2005;6(8):493-6
96. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomized, double-blind, placebo-controlled study. Pain 2001;94:215-24
97. Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:981-8
98. Haughton LA, Fell C, Whorwell PJ, et al. Effect of a second-generation alpha-2-delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007;56:1218-25
99. Tsuchiya J, Barreto R. Okura R. et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004;5:169-74
100. O'Mahony L, Mccarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51
101. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-90
102. Cash BD, Schoenfeld PS. Alternative medical therapies for dyspepsia: a systematic review of randomized trials. In: Johnson DA, Katz PO, Castell DO, editors, Dyspepsia. Philadelphia: American College of Physicians; 2001. p. 159-75
103. Palsson OS, Turner MJ, Johnson DA, et al. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 2002;47:2605-14
104. Keefer L, Blanchard EB. A one year follow-up of relaxation response meditation as a treatment for irritable bowel syndrome. Behav Res Ther 2002;40:541-6
105. Wilson S, Maddison T, Roberts L, et al. Systematic review. the effectiveness of hypnotherapy in the management of irritable bowel syndrome. Aliment Pharmacol Ther 2006;24:769-80
106. Xiao WB, Liu YL. Rectal hypersensitivity reduced by acupoint TENS in patients with diarrhea-predominant irritable bowel syndrome: a pilot study. Dig Dis Sci 2004;49:312-9
107. Chan J, Carr I, Mayberry JF. The role of acupuncture in the treatment of irritable bowel syndrome: a pilot study. Hepatogastroenterology 1997;44:1328-30
108. Forbes A, Jackson S, Walter C, et al. Acupuncture has a placebo effect on rectal perception but not on distensibility and spatial summation: a study in health and IBS. Am J Gastroenterol 2005;11:4040-4